Skip to main content
Evidence Based Longevity (EBL)Check what I take
← All protocols
B

Protocol

Testosterone therapy for men with low testosterone and low sex drive

In two randomized trials of men with low testosterone, testosterone gel improved sexual activity and sexual desire against placebo An inactive substitute made to look like the real treatment, so participants cannot tell which one they received.: the Testosterone Trials (790 men aged 65 or older, 1 year) and the TRAVERSE sexual function study (1,161 men aged 45 to 80 with low libido, effect held at 24 months).

Compare this record with another, side by side →

At a glance

In plain words

Some men have low testosterone and a low sex drive. In two trials, testosterone gel gave them more sex and more desire than a dummy gel, and the effect lasted two years. It did not give them more energy. In the largest trial it did not raise heart attacks or strokes. But men on it had more irregular heartbeat, kidney problems, lung clots and broken bones.

The letter, taken apart
What was measured
Sexual acts per day, recorded by the men on a daily questionnaire.
How big
Sexual activity rose by 0.49 acts per day at 6 months and 0.47 at 12 months more than with placebo.Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 37589949.
Who it applies to
Men aged 45 or older with low testosterone, symptoms and low sex drive.
Safety
More irregular heartbeat, kidney injury, lung clots and fractures in the largest trial.
The record in one view
Compared with
A placebo gel.
Certainty
Grade B, resting on: Two randomized placebo-controlled trials with self-reported sexual outcomes, plus a large safety trial.
What would change this grade
Could rise to A with: Randomized trial of testosterone. Who: Men with low testosterone and low libido. Measured: Sexual activity recorded by a validated objective method. Length: At least 12 months.
Cost
No price recorded yet.
Sources
4 studies cited on this record, listed under Sources.
For clinicians
A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.
BSelf-report Grade B

In two randomized trials of men with low testosterone, testosterone gel improved sexual activity and sexual desire against placebo: the Testosterone Trials (790 men aged 65 or older, 1 year) and the TRAVERSE sexual function study (1,161 men aged 45 to 80 with low libido, effect held at 24 months). In TRAVERSE as a whole, testosterone did not raise major heart events, but atrial fibrillation, acute kidney injury, blood clots in the lungs and fractures were more common.

Why this letter

Why this gradeThe reasoning, and what the grade does not cover.
Why this grade

Grade B on sexual activity in men with low testosterone and low sex drive. The TRAVERSE sexual function study found more sexual activity with testosterone at 6, 12 and 24 months (Pencina et al., 2023; PMID 37589949), and the Testosterone Trials found the same in men aged 65 or older (Snyder et al., 2016; PMID 26886521).

WHY NOT Asexual activity is recorded by the men themselves on a questionnaire, a self-reported endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. that caps at B. FUNDING: TRAVERSE was funded by AbbVie, a maker of testosterone gel. HARMS: in TRAVERSE, atrial fibrillation, acute kidney injury and pulmonary embolism were more common with testosterone (Lincoff et al., 2023; PMID 37326322), and clinical fractures were more common (HR 1.43; Snyder et al., 2024; PMID 38231621).

WHAT THIS GRADE DOES NOT COVERenergy and vitality, which did not improve; erectile function, which improved in one trial and not the other; men with normal testosterone; and muscle, bone or longevity claims, which these trials do not support.

A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →

Who responds: this record's trial reading reports no subgroup that identifies who responds.

Evidence notes: randomized trial, industry-sponsored

Endpoint graded: Sexual activity (daily questionnaire) (self_report)

Last reviewed: November 2026

Evidence wanted

The trial that would change this grade.

DesignRandomized trial of testosterone
PopulationMen with low testosterone and low libido
EndpointSexual activity recorded by a validated objective method
DurationAt least 12 months

Positive trials of this shape from independent research groups would move this entry to A.

Why the current trials fall short

Self-reported outcomes cap the letter at B.

Clinical trials

ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Testosterone among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.

Search recruiting studies of Testosterone on ClinicalTrials.gov

Dose, form and timing

What to track

Testosterone level, hematocrit, heart rhythm symptoms, and fracture risk factors.

As studiedDose, form, population and duration for every use.
As studied
FormTestosterone gel applied to the skin daily: 1.62% gel in TRAVERSE (PMID 37589949); gel adjusted to mid-normal levels in the Testosterone Trials (PMID 26886521).
Dose1.62% testosterone gel applied daily (PMID 37589949); gel dose adjusted to raise testosterone into the mid-normal range for men aged 19 to 40 (PMID 26886521).
PopulationMen aged 45 to 80 with testosterone below 300 ng/dL and low libido (PMID 37589949); men aged 65 or older below 275 ng/dL (PMID 26886521).
DurationUp to 24 months (PMID 37589949); 12 months (PMID 26886521).

A grade describes the intervention that was tested. Where the product on the shelf differs from it, this says so.

Safety

Safety evidence, by strength

Cautions documented in human studies. Each caution on this record, sorted by what it rests on.

Documented in human studies
Cautions resting on what randomized trials or large studies found in people.
  • Atrial fibrillation, acute kidney injury and pulmonary embolism more common with testosterone in TRAVERSE (PMID 37326322)
  • Clinical fractures more common with testosterone in TRAVERSE (3.50% against 2.46%) (PMID 38231621)
Suspected from case reports
Harms reported in individual patients or uncontrolled observations, not confirmed by a trial.

None recorded.

Mechanistic only
Cautions reasoned from how it works, with no human harm data behind them.

None recorded.

Population cautions
Groups in whom it has not been studied, so its safety there is unknown.
  • Men with prostate cancer, high hematocrit or untreated sleep apnea were excluded from the trials
No safety data

Does not apply: human harm data are listed above.

Grade history

How this letter has changedLatest: No. 472 · November 2026 · First graded.
Grade history
No. 472 · November 2026 · First graded
Testosterone therapy for men with low testosterone and low sex drive is added from the gap report: Grade B

New record in the gap-report batch. In two randomized trials of men with low testosterone, testosterone gel improved sexual activity and sexual desire against placebo: the Testosterone Trials (790 men aged 65 or older, 1 year) and the TRAVERSE sexual function study (1,161 men aged 45 to 80 with low libido, effect held at 24 months). In TRAVERSE as a whole, testosterone did not raise major heart events, but atrial fibrillation, acute kidney injury, blood clots in the lungs and fractures were more common.PMID 37589949 PMID 26886521 PMID 37326322 PMID 38231621

Every change to a letter on this site is dated and published. The full evidence log →

Sources

How this record was checked
Citations
Every paper cited on this page is matched to its PubMed record on every build.
Retractions
None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
Read against the papers
November 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
Outside review
Not yet done. No reviewer outside EBL has checked this record.

What each of these checks can and cannot show: evidence integrity.

The evidence, in fullFour papers, each linked to its PubMed record.
The evidence

Pencina et al. (J Clin Endocrinol Metab, 2023; PMID 37589949): TRAVERSE Sexual Function Study, 1,161 men aged 45 to 80 with hypogonadism and low libido, 1.62% testosterone gel against placebo; sexual activity 0.49 (95% CI 0.19 to 0.79) and 0.47 (0.11 to 0.83) more acts per day at 6 and 12 months, maintained at 24 months; desire improved, erectile function did not. Snyder et al. (N Engl J Med, 2016; PMID 26886521): Testosterone Trials, 790 men aged 65 or older with testosterone below 275 ng/dL, testosterone or placebo gel for 1 year; sexual activity, desire and erectile function increased; no benefit for vitality. Lincoff et al. (N Engl J Med, 2023; PMID 37326322): TRAVERSE, 5,246 men; major cardiovascular events HR 0.96 (non-inferior); higher incidence of atrial fibrillation, acute kidney injury and pulmonary embolism. Snyder et al. (N Engl J Med, 2024; PMID 38231621): TRAVERSE fracture analysis, clinical fracture 3.50% against 2.46% (HR 1.43, 95% CI 1.04 to 1.97); funded by AbbVie and others.

How EBL searched for the trials (1 search)

The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.

Searched PubMed in November 2026. 8 records screened, 2 eligible for the graded claim.
Query: testosterone[tiab] AND (sexual[tiab] OR libido[tiab]) AND hypogonad*[tiab] AND randomized controlled trial[pt]
The 8 most recent records were screened by title; the TRAVERSE sexual function study (PMID 37589949) and the Testosterone Trials (PMID 26886521) are the reference trials.
PubMed watch: does a new study change the grade? (nothing new)

No new paper matching the search behind this grade has been added to PubMed since November 2026.

Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.

Who paid for these trials

For each trial behind a letter on this page, the funding its PubMed record lists. "No funder" means PubMed lists none, not that the trial had no funding.

  • Pencina et al., 2024, J Clin Endocrinol Metab (PMID 37589949): PubMed lists funding from AbbVie, Inc; Boston Claude D. Pepper Older Americans Independence Center; US National Institutes of Health (National Institute on Aging).
  • Snyder et al., 2016, N Engl J Med (PMID 26886521): PubMed lists funding from National Institutes of Health and others; US National Institutes of Health (National Institute on Aging); US National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Diseases); US National Institutes of Health (National Center for Advancing Translational Sciences); US National Institutes of Health.
  • Lincoff et al., 2023, N Engl J Med (PMID 37326322): PubMed lists funding from AbbVie and others.
  • Snyder et al., 2024, N Engl J Med (PMID 38231621): PubMed lists funding from AbbVie and others.

Disclosure

Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.

Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy

© Evidence Based Longevity, Inc. All rights reserved

Medical disclaimer

These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.

Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →

Build 9b19d78, November 2026